



**“Policies and programmes in the field of
Personalized Medicine: first results of the
mapping activities of the IC2PerMed
project”**

23rd November 2020



This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874694

23.11.2020

10:50 – 11:05

**SHIFTING THE MAPPING RESULTS IN A ROADMAP FOR PM: NEXT
STEPS FOR THE KNOWLEDGE SYNTHESIS ON THE IDENTIFICATION,
TRANSFERABILITY AND SCALING UP OF INTERNATIONAL
STANDARDS IN PM**

Dr. Chiara Cadeddu

Università Cattolica del Sacro Cuore – UCSC



This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874694

WP 2- Knowledge synthesis on the identification, transferability and scaling up of international standards in personalized medicine

Aim: co-designing the appropriate framework and strategies fostering Chinese integration in ICPerMed consortium is the core objective of WP2. EU and Chinese high-level experts engaged within this WP will set the path for qualifying standards, approaches and priorities for collaboration.


Specific objectives:

1. Setting up Working Groups that will support the Consortium towards the common definition, approaches and thematics for EU-Chinese research collaborations
2. Analysing and discussing frameworks and potential recommendations aligned with ICPerMed Action plan priorities towards policy makers
3. Co-defining the IC2PerMed Roadmap for the uptake of PM approaches in health

Project developments: Where are we?

Mapping of Personalised Medicine's policies and programmes in Europe and China

Working groups:
Community of EU and Chinese PM stakeholders analysing and designing a roadmap for developments upon PM R&I schemes for facilitating the integration of Chinese stakeholders in ICPeMed activities by the relevant agencies



Delegation visits
Creating a solid framework for collaboration formalising engagement of relevant Chinese stakeholders within the ICPeMed initiative

Expertising: The strategy



02. Expertising

Building upon exchanges between experts in PM domains for fostering actionable approaches

- ✓ In each WG High-level experts in their field will work together with members of IC2PerMed on developing overarching strategies and solutions for their specific topic.
- ✓ Groups Co-chaired by a representative from a European and a Chinese counterpart of the IC2PerMed Project - Coordination among WGs will be ensured by the two Co-Chairs.

Overview of the Working Groups



Working Group 1: SHAPING SUSTAINABLE HEALTHCARE (PEOPLE AND ORGANISATION)

Aim: To define a common *organizational* strategy to support a *sustainable* translation of PM from *research* to *practice* at 3 levels:

- 1) Micro: Hospitals, healthcare facilities
- 2) Meso: Integrated care, local authorities
- 3) Macro: Health system

Guiding IC2PerMed partners: UCSC and Tsinghua

WG1: a three dimensional outlook



I. AWARENESS AND EMPOWERMENT

Focus is on: Defining common approaches to maximise engagement of citizens and patients, both in the preventive and curative care.

Goal: To include the perspective of citizens, patients and patient organisations in the decision-making processes of public health authorities and to enable a more efficient interaction between them and researchers/healthcare organisations.

II. EDUCATION AND CURRICULA

Focus is on: Defining common advanced major changes in **medical and other healthcare provider curricula** (e.g. pharmacists, nurses, biologists and professionals involved in the rehabilitation programs) due to:

- The major technological advances in PM
- Necessity of multidisciplinary teams (bioengineers, statisticians, digital professionals ecc)

Goals:

1. To educate a **new generation** of healthcare professionals (long term uptake)
2. To update **current professionals** with lifelong learning programmes (faster uptake)

III. PM IN SUSTAINABLE HEALTHCARE

Focus is on: Harmonising strategies and practices to ensure that PM provides **added value** to health systems by fostering their effectiveness, efficiency and sustainability.

Goal: To understand key contextual factors and barriers at **Micro, Meso and System organisational levels** in order to *sustainably* translate PM into routine clinical practice.

Overview of the Working Groups



Working Group 2: INNOVATION & MARKET

Aim: To discuss

- 1) The international standards, regulatory aspects and market barriers of **medical, genetic and environmental data schemes** as inputs for **diagnosis, treatment, prognosis and drugs developments.**
- 2) Health economic models that can be applied both in EU and China with specific focus on **pricing, insurance coverage and reimbursement.**

Guiding IC2PerMed partners: S2i and BGI

WG2: a bi-dimensional outlook



I. BIG DATA AND ICT SOLUTIONS:

Focus is on: Encouraging a **harmonised** and **fast** uptake of technologies for data capture, storage, harmonisation, management and data processing

Goal: Define common decision support tools and methodologies for **physicians and public health authorities** in their decision-making process.

II. BRINGING INNOVATION TO MARKET:

Focus is on: From research, development, regulatory approval and **HTA** up to definition of **reimbursement** mechanisms and **implementation** decisions (including regulatory and legal frameworks and guidance)

Goals:

- To **speed up** the integration innovative solutions into the Chinese and European PM markets
- To enable **companies** to such markets with sustainable business plans.

Overview of the Working Groups



Working Group 3: RESEARCH AND CLINICAL STUDIES IN PM

Aim: To align **clinical research** domains (i.e classification, trials, programmes) collaboration correlated to **bio-banking** (to be further developed in the ‘concrete collaboration case’ of the project).

Guiding IC2PerMed partners: FTELE and NCC

WG3: a bi-dimensional outlook



I. TRANSLATING BASIC TO CLINICAL RESEARCH AND BEYOND:

Focus is on:

- i) developing methods to **integrate and evaluate** genomic, epigenetic, transcriptomic, proteomic, metabolomic and microbiome analyses;
- ii) harmonising **biomarker** evaluation and validation processes;
- iii) encouraging the development of **international longitudinal studies** by harmonising clinical trial designs, sampling procedures, data exchange and reimbursement.

Goal:

Standardising approaches to **translate basic to clinical research**

II. RESEARCH FUNDING

Focus is on: aligning research funding priorities and procedures in the field of PM across the relevant Funding Agencies in EU and China.

Goal:


Development of recommendations for policy makers on personalised medicine implementation

HOW DO WE SHIFT THE MAPPING RESULTS IN A ROADMAP FOR PM?

02. Expertising

Building upon exchanges between experts in PM domains for fostering actionable approaches

- 1) Set up of **regular meetings among WGs** (most likely remotely) - minutes of the meetings and working documents will be shared among the WGs to ensure synergies, integration among procedures and avoid duplication
- 2) Release **Position papers** on WGs' topics - Release of 6 position papers and of a strategic workplan to foster collaboration between ICPerMed and China on PM (Task 2.2 - D2.2 [M24]):
 - *Relative Milestone [M18]: By Month 18, WG position paper outlines will be issued and feedbacks from funding agencies and policy makers gathered will be included in the final recommendations, issued by the experts and disseminated through the website of the project*
- 3) Organization of "**Harmonisation/Alignment workshop**" to discuss position papers on the challenges presented and discussed in a unique event participated by all the WGs members
- 4) Synthesized of Position Papers in a logical sequence of actions that can be concretely undertaken and are outlined in the "**IC2PerMed Roadmap**", as a basis for interactions with ICPerMed and Chinese Working Agencies in the WP3 (Task 2.3 - D2.3 [M30]). The roadmap will be shared and discussed with relevant stakeholders in the "**IC2PerMed Roadmap Validation**" Workshop.




WHERE DO
WE GO
FROM
HERE?



To make sure our collaboration begins on a solid and valuable base of evidence, we kindly ask you to validate our mapping findings for your country through a

SURVEY

that you will be receiving shortly after this workshop



Thank you for your attention!

Questions, comments, suggestions?



www.ic2permed.eu



Twitter: twitter.com/IC2PerMed

LinkedIn: IC2PerMed group



chiara.cadeddu@unicatt.it